TickerTalks
Browse all tickers →
TickerTalks›$ABVX
ABABVX

Abivax S.A.

$ABVX·$9.6B·Biotechnology·Healthcare
$111.73-1.4%YTD-11.2%1Y+43.9%
Mentions · last 7 days
2026-08-21: 96 posts2026-08-22: 42 posts2026-08-23: 34 posts508-3%
Price updated 1h ago·X counts updated 8d ago
ABABVX
$ABVXAbivax S.A.
$111.73-1.43%508 posts-3%
AI analysisFundamentalsVoices on X
Loading…

AI verdict & sentimentAI analysisGenerated by AI from underlying data

Top X posts

Today's AI verdict on what's driving $ABVX, plus how loud the X conversation is and which way it's leaning.

AI analysis

TickerTalks’ read on the fundamentals and what’s driving the move.

Hinges on a big eventWinding up for a moveAI verdict · as of 2026-08-31

Trading in a tight range and building pressure — a move looks likely soon, but the direction isn't clear yet.

A French biotech with $920M cash, an obefazimod Phase 3 UC package, and a Crohn's Phase 2 readout that either resets the equity higher or drops it back to $80.

Abivax is a French clinical-stage biotech listed on Nasdaq via ADS, developing obefazimod (formerly ABX464) for ulcerative colitis (UC), Crohn's disease, and inflammatory conditions. The recent equity story has been a re-rating from mid-2025 obefazimod UC Phase 3 data, followed by a large capital raise and a quiet holding pattern awaiting the next readout.

  • Revenue is zero and the burn is real: the company is pre-launch with -$0.71 to -$1.19 quarterly EPS in recent quarters and consensus modeling $3.8M FY26 revenue, so the equity trades entirely on the pipeline optionality and the cash balance behind it.
  • The July capital raise reset the balance sheet: an $800M ADS offering priced at $125 per ADS took cash to roughly $920M (CEO framed it as enough to prepare a solo US launch instead of relying on a buyer) — that removes the funding overhang most catalyst-play biotechs carry into a readout.
  • The Crohn's Phase 2 readout is the near-term catalyst: bulls lean on a Rinvoq/Skyrizi-style Novartis or Merck buyout playbook if the data extends the UC efficacy story into a second indication; bears cite a 50% jump in short interest to about 6M shares and NPV math that struggles to justify above $150-$160.
  • The Sofinnova 13D/A Amendment No. 6 disclosure shows continued high-conviction anchor-investor engagement, but there are no reported insider buys or sells in the corporate window — a stop-selling signal from the largest holder is what has kept the equity coiled rather than breaking.

The path if it works is a clean Crohn's Phase 2 readout at the Sept 21 timeline plus a Novartis or Merck partnering framework — the equity reprices toward the $150+ range NPVs support. What breaks the setup is a mixed Crohn's readout with no buyout counterparty engaged and the September/October bearish put flow proving prescient — that's when a name at 55% of its 52-week range gives back to the $80s where the last leg started.

Agrees with X sentimentThe mixed X read is honest: bulls citing the ulcerative colitis data, the potential Novartis/Merck fits, and the Rinvoq/Skyrizi playbook, versus bears pointing to bearish September/October put flow, a 50% jump in short interest to about 6M shares, and shrinking NPV math above $150-$160 — both sides describe the same event-driven setup, which is why 'BioX drama' is the recurring word in the crowd's own framing.

What to watch: The Sept 21 Crohn's Phase 2 readout — a clean data point plus a partnering framework repositions the equity toward the $150+ range; a mixed readout with no buyout counterparty engaged is what breaks the coil and gives back to the $80s where the last leg started.

On the calendar: 2026-09-21 — Crohn's Phase 2 readout

X sentiment

What the X crowd is saying right now — descriptive, summarised from the day’s posts.

Mixed sentiment79 posts analyzed · as of 2026-08-30

Abivax posters are visibly bag-holding into a Crohn's Phase 2 readout with no confirmed buyout, and the mood swings between resignation and hope. Bulls lean on the ulcerative colitis data, potential fits with Novartis or Merck as an Abbvie-style Rinvoq/Skyrizi playbook, and TD Cowen-style peer chatter. Bears point to bearish September/October put flow, a 50% jump in short interest to about 6M shares, and shrinking NPV math above $150-$160. "BioX drama" is the recurring word.

Read the AI verdict + X sentiment for $ABVX

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • X crowd read with bullish/bearish call + post volume
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Develops anti-inflammatory drugs for chronic immune diseases, with obefazimod in late-stage trials for ulcerative colitis.

Industry overviewAI analysisGenerated by AI from underlying data

Where Biotechnology sits in its cycle right now — and what that implies for $ABVX.

Biotechnology · Healthcare

GLP-1 oral formulation competition — emerging clinical data from pipeline challengers — is the central bifurcation: platform holders (LLY, NVO) defend on efficacy breadth while precision oncology names decouple entirely. FDA catalyst cadence over the next 60 days sets the near-term tone.

What this means for $ABVX

Partial — fee-based midstream revenue has limited direct commodity price exposure but volume ties to upstream production activity.

Top industry ETF

$IBBiShares Biotechnology ETF
+12.1%YTD
+51.2%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
-18.2How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
-48.0%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
0.0%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
-2.3%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
0.0Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
-165%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
0.0%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
0.1Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q1 2026May 22, 2026$-0.71$-1.07+33.6%
Q4 2025Mar 23, 2026$-1.19$-1.70+30.0%
Q3 2025Dec 15, 2025$-2.47$-0.79-214.3%
Q2 2025Sep 8, 2025$-0.86$-0.90+4.4%
Next earningsMon, Sep 21·consensus EPS $-0.96

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q4 FY25$0-100.0%——$-2.10$-71.3M
Q2 FY25$0-100.0%——$-1.59$-66.7M
Q4 FY24$0-100.0%——$-1.50$-69.3M
Q2 FY24$0-100.0%——$-0.65$-42.7M

Forward consensus

5-year forecast · up to 11 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$3.8M$1.6M – $8.3M-$3.30-$3.84 – -$2.7510
FY27$105.5M$17.5M – $193.4M-$3.06-$4.53 – -$2.0510
FY28$505.9M$218.9M – $1.3B$0.41-$0.36 – $1.9011
FY29$1.2B$499.3M – $3.1B$6.53$1.44 – $19.165
FY30$1.6B$655.8M – $4.1B$8.41$1.85 – $24.675

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.1.0×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.55%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.-8.2%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.-5.0%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatMid float · 67.1M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today1.4% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β-0.235-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.FilingActive offeringA shelf registration (S-3 / S-3ASR / S-1) or prospectus supplement (424B*) was filed in the last 90 days — the company is registered to (or actively) issuing new shares. Dilution risk.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

SC 13D/AActivist amendmentJul 6SC 13D/A
AI summary

Sofinnova Crossover I SLP (a French investment fund) and related entities — including management company Sofinnova Partners SAS — filed Amendment No. 6 to their Schedule 13D for Abivax S.A. (ABVX) as of July 2, 2026, reporting aggregate voting rights of 3,535,843 representing 4.3% of the outstanding class, based on 82,130,598 voting rights outstanding as of May 31, 2026. The fund directly owns 2,474,299 ordinary shares/ADRs (with sole dispositive power), with voting rights exceeding shares due to Abivax's dual-vote structure. Sofinnova Partners SAS holds sole voting and dispositive control as management company. This is a routine update to a pre-existing passive institutional holder position — the French VC firm is not signaling activist intent.

424B5Prospectus supplement (offering)Jul 2424B5
AI summary

Abivax S.A. (ABVX), a French biotech traded on Euronext Paris and Nasdaq, is offering 6,400,000 ADSs (each representing one ordinary share) at $125.00 per ADS, raising approximately $800 million gross ($762 million net of $38 million in underwriting discounts). Joint bookrunners include Leerink Partners, Morgan Stanley, Piper Sandler, and Guggenheim Securities; delivery was expected on or about July 6, 2026. Underwriters hold a 30-day option for up to 960,000 additional ADSs. This is a significant dilutive capital raise likely funding clinical advancement or commercial expansion of Abivax's inflammation pipeline.

424B5Prospectus supplement (offering)Jun 30424B5
AI summary

Abivax (French biotech, Euronext Paris + Nasdaq) filed a preliminary 424B5 for a $600M ADS offering; joint bookrunners include Leerink Partners, Morgan Stanley, Piper Sandler, and Guggenheim Securities; registered direct offering structure with delivery expected July 2026. Significant dilutive capital raise for a commercial-stage biotech with transatlantic listing; proceeds likely support U.S. commercialization of obefazimod, its lead inflammation drug.

SC 13D/AActivist amendmentMay 11SC 13D/A
AI summary

Sofinnova Crossover I SLP filed an amended Schedule 13D on ABVX disclosing beneficial ownership (5,499,478.00 shares) as of 2026-05-11. The filer's stated intent is passive investment with no plan to influence control of the company.

+ 13 other (8 6-Ks · 2 13Gs · 1 POSASR · 1 S-8) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

Abivax SA Sponsored ADR (NASDAQ:ABVX) Given Average Recommendation of “Moderate Buy” by Brokeragesdefenseworld.net·5d agoAbivax: Obefazimod Goes The Distance And So Does My Buy Ratingseekingalpha.com·46d agoShould You Buy Abivax SA Sponsored ADR (ABVX) After Golden Cross?zacks.com·52d agoAbivax $920 million cash haul lets it prepare for solo U.S. launch instead of relying on a buyer, CEO tells CNBCcnbc.com·53d ago3 Soaring Stocks That May Have More Upside Aheadfool.com·55d ago

More in Biotechnology

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$MRNA$ALT$AURA$IOVA$NWBO$SLS$AMLX$ABCL
Voices on X · top 15 · last 7 days

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport